Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide and Sunitinib in RTKI-Resistant Renal Cell Carcinoma
NCT06222593Phase 2Recruiting
- Sponsor
- University at Buffalo
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bicalutamide in renal cell carcinoma (RCC), sponsored by University at Buffalo. Started Oct 2024; status: recruiting.
02
Drugs
bicalutamide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06222593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222593.